Yahoo Finance

Featured Company News - IMRALDI(R), Biogen's Version of AbbVie's Humira(R), Approved in the European Union

Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected ObsEva SA (NASDAQ: OBSV) for due-diligence and potential coverage as ...
Business Insider

IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union

BAAR, Switzerland, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Samsung Bioepis Co. Ltd, a joint venture between Samsung BioLogics and Biogen (Nasdaq: BIIB) today announced the European launch of IMRALDI TM, an ...
Pharmabiz

EMA committee recommends approval of Biogen's Imraldi, an adalimumab biosimilar candidate referencing Humira

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Imraldi (also known as SB5), an adalimumab biosimilar candidate ...
Business Wire

Samsung Bioepis and Biogen Announce Pooled Analysis Results of Anti-TNF Biosimilars BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) at EULAR 2018

Since the European Commission granted marketing authorization for BENEPALI and FLIXABI in 2016, the two biosimilars have treated nearly 80,000 patients across 23 countries. i In addition, Samsung ...
elEconomista

IMRALDI®, Biogen´s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union

IMRALDI has been developed by Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen (NASDAQ, BIIB) and is approved for the treatment of rheumatoid arthritis (RA), juvenile idiopathic ...
Reuters

Imraldi, Biogen's Adalimumab Biosimilar referencing Humira, is approved in EU

OpenAI is planning its biggest ChatGPT overhaul yet, aiming ‌to turn it into a "superapp" with coding tools and AI agents to boost revenue ⁠ahead of a planned share listing, the Financial Times ...